A5075997330- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Breast Cancer Treatment Studies
- COVID-19 Clinical Research Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Glioma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Cancer-related Molecular Pathways
- Radiopharmaceutical Chemistry and Applications
- Multiple Myeloma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Medication Adherence and Compliance
- Monoclonal and Polyclonal Antibodies Research
- Research on Leishmaniasis Studies
- Immune cells in cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Dialysis and Renal Disease Management
- Testicular diseases and treatments
Hacettepe University
2021-2025
Hacettepe University Hospital
2023-2025
Cancer Institute (WIA)
2024-2025
GTx (United States)
2024
Glioblastoma multiforme (GBM) is a tumor with high refractory rate to immunotherapy and low mutational burden phenotype, leading limited immunogenic neoantigens. The present study aimed investigate the sequential use of bevacizumab in patients GBM, exploring clinical outcomes potential complications. Patients received various combinations after standard treatment, including surgery, radiotherapy temozolomide. Clinical courses, radiological findings treatment were monitored documented during...
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for solid tumors, offering substantial survival benefits. Despite this progress, many patients do not achieve durable responses, highlighting need novel prognostic biomarkers. This study investigates association between serum sodium levels and outcomes in treated with ICIs. We conducted a retrospective cohort involving 509 metastatic tumors assessed overall (OS), progression-free (PFS), response rates using...
Colorectal cancer (CRC) ranks third in global prevalence, with 40% presenting as metastatic colorectal (mCRC). KRAS mutations mCRC patients confer resistance to anti-EGFR treatments. Promising inhibitors such sotorasib and adagrasib targeting KRASG12C have demonstrated efficacy. Herein, we present a heavily pretreated case progression-free survival of 12 months panitumumab. In 2017, 27-year-old male presented abdominal pain received diagnosis stage IIIC G12C mutant CRC. Following surgery...
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is MONALEESA-7 study, and data palbociclib limited. Data are also limited regarding whose dose was reduced due to neutropenia, most common side effect inhibitors. In our we aimed evaluate ribociclib reduction neutropenia progression-free survival. Our a multicenter, retrospective factors affecting survival...
Trastuzumab emtansine (T-DM1) is a mainstay therapy for HER2-positive metastatic breast cancer (mBC). However, identifying patients who will benefit most remains challenge due to the lack of reliable biomarkers. The recently developed pan-immune-inflammation value (PIV), novel immune-inflammation marker, could aid in this regard, considering immunomodulatory effects T-DM1. Therefore, we aimed evaluate association between PIV and efficacy T-DM1 with mBC. A total 122 mBC treated were included....
Abstract Purpose This study aimed to assess the effects of concurrent opioid analgesic (OA) use with immune checkpoint inhibitors (ICIs) on progression-free survival (PFS) and overall (OS). Methods In this observational retrospective study, we included advanced cancer patients who received ICIs at Hacettepe University Hospital’s Department Medical Oncology between June 2018 January 2023. Results Our 375 recurrent or metastatic treated in first, second line, beyond. There were no significant...
Polypharmacy is a common problem in older cancer patients, although the data about polypharmacy and potentially inappropriate prescription practices limited patients treated with immune checkpoint inhibitors (ICIs). Therefore, we aimed to evaluate frequency drug-drug interactions (≥65 years) ICIs.A total of 70 geriatric advanced were included. The was defined as regular use 5 or more drugs. START/STOPP Criteria Version 2 used for medications (PIM) potential omissions (PPO). Medscape Drug...
The albumin-globulin ratio (AGR) could be a prognostic biomarker in patients with cancer, although the data is limited treated immune-checkpoint inhibitors (ICIs).We aimed to evaluate association between AGR and survival ICI-treated patients.The of 212 advanced-stage were retrospectively evaluated this cohort study. overall (OS) progression-free (PFS) multivariate analyses. Additionally, receptor operating curve (ROC) analysis was conducted assess AGR's predictive power very early...
Abstract Background The objective of this study is to assess the correlation between survival outcomes and sACR in patients who are treated with immune checkpoint inhibitors (ICIs). Methods This was conducted on individuals were administered ICI at least 3 doses from 2018 2023. Serum-albumin creatinine ratio (sACR) measured using serum albumin values before immunotherapy. Based median level, divided into two groups: sACR-High sACR-Low. relationship progression-free (PFS) overall (OS),...
The fact that the human epidermal growth factor receptor 2 (HER2)-low group, historically classified as HER2 negative in breast cancer histology, benefited from HER2-targeted treatments similarly to HER2-positive group indicates this has a distinct histology HER2-0 group. effectiveness of cyclin-dependent kinase 4/6 inhibitors, which are standard first-line treatment for hormone receptor-positive, HER2-negative advanced cancer, newly defined histological subgroup remains topic debate. In our...
Multiple myeloma (MM) is a clonal proliferation of plasma cells in the bone marrow, with criteria including marrow ≥10% or biopsy-proven plasmacytoma myeloma-defining events. Solitary (SP) represents singular cell lesion without events, while extramedullary disease (EMD) an aggressive form MM characterized by independent growth outside microenvironment. We present unique case 64-year-old patient bilateral testicular anteceding development Immunoglobulin G (IgG) kappa-type MM, featuring renal...
Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer represents the most prevalent subtype of cancer. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, in combination with endocrine therapy (ET), have shown substantial benefits improving progression-free survival and, for ribociclib, an overall advantage. Despite clinical benefits, ribociclib is associated elevated liver enzymes and severe dysfunction. We present a 44-year-old Caucasian woman...
The prognostic role of preoperative carcinoembryonic antigen (CEA) in breast cancer is recognized, but the impact postoperative CEA levels on survival early uncertain.
Recent observational studies reported acute kidney injury (AKI) events in over 10% of the patients treated with immune checkpoint inhibitors (ICIs). However, these included high-resource settings and earlier lines. Therefore, we aimed to assess AKI rates predisposing factors ICI-treated from a limited resource setting. We evaluated 252 advanced cancer for this retrospective cohort study. were defined by Kidney Disease Improving Global Outcomes criteria. The median age was 59 years. melanoma...
Abstract Background and Aims The immune checkpoint inhibitors (ICIs) became a vital part of cancer treatment. ICIs seem to be safer than chemotherapy for kidneys in clinical trials. However, recent observational studies from high-resource settings pointed out the possible underreporting renal adverse events like acute kidney injury (AKI) trials due focusing only immune-related events. Additionally, generally enroll fitter population with lesser comorbidities include mostly treatment-naive...